Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland-Reference-Cited by-同舟云学术

Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland

Published:2023-01 Issue: Volume:Volume 15 Page:1-13
ISSN:1178-6981
Container-title:ClinicoEconomics and Outcomes Research
language:en
Short-container-title:CEOR

Author:

Hallinen Taru,Kivelä Santtu,Soini Erkki^ORCID,Harjola Veli-Pekka,Pesonen Mari

Publisher

Informa UK Limited

Subject

Health Policy,Economics, Econometrics and Finance (miscellaneous)

Reference40 articles.

1. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

2. Heart Failure. Current Care Guidelines. Working group set up by the Finnish Medical Society Duodecim and the Finnish Cardiac Society. Helsinki: The Finnish Medical Society Duodecim; 2017. Available from: https://www.kaypahoito.fi/hoi50113. Accessed April 14, 2021.

3. Heart failure in Finland: clinical characteristics, mortality, and healthcare resource use

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of empagliflozin in the treatment of Malaysian patients with chronic heart failure and preserved or mildly reduced ejection fraction;PLOS ONE;2024-08-23

2. The Impact of the Withdrawal of SGLT2 Inhibitors on Clinical Outcomes in Patients with Heart Failure;Journal of Clinical Medicine;2024-05-29

3. Cost‐effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA‐HF and DELIVER data;European Journal of Heart Failure;2024-03

4. Empagliflozin cost‐effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction;ESC Heart Failure;2023-11-15

5. Is Using Sodium-Glucose Cotransporter-2 Inhibitors to Treat Adults with Chronic Heart Failure Cost-Effective? A Systematic Review of Cost-Effectiveness Studies;Applied Health Economics and Health Policy;2023-08-30